Gallium-68 satoreotide

N/A

Report date: 2025/11/28 15:16:16

NME

Base Information

Drug NameGallium-68 satoreotide

Drug Alias Name[68Ga]Satoreotide trizoxetan68Ga-satoreotideSOMscan68Ga-Satoreotide trizoxetan68Ga IPN-1070 +[8]

ClassificationDiagnostic agent (In vivo)Radiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Gallium > 68Ga +[5]

Mechanisms of ActionSomatostatin receptor 2 antagonists

TargetsSomatostatin receptor 2

Therapy Area/IndicationsGastroenteropancreatic neuroendocrine tumorSmall Cell Lung CarcinomaBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumUnited StatesDenmark +[9]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesIpsen Inc

China Registration ClassN/A

Develop Information

Active CompaniesAriceum Therapeutics Australia Pty Ltd

Inactive CompaniesIpsen

Active IndicationsSmall Cell Lung Carcinoma

Inactive IndicationsGastroenteropancreatic neuroendocrine tumorBreast Neoplasms

Other Information

ATC CodeN/A